



References

Page 1: Background

1. National Institute for Care and Health Excellence. Depression in adults: recognition and management. Clinical guidelines [CG90]. 2018. [Internet]. <https://www.nice.org.uk/guidance/cg90/>
2. Kennedy S, Lam R, McIntyre R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Section 3. Pharmacological Treatments. *Can J Psychiatry* 2016;61:540-560
3. VA/DoD Clinical practice guidelines for the management of major depressive disorder. 2016. [Internet]. <https://www.healthquality.va.gov/guidelines/MH/mdd/>
4. Malhi G, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Australian New Zealand J Psychiatry* 2015;49:1-185
5. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Third Edition. 2010. [Internet]. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
6. Qaseem A, Snow V, Denberg T, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2008;149:725-733
7. Eveleigh R, Muskens E, Lucassen P, et al. Withdrawal of unnecessary antidepressant medication: a randomised controlled trial in primary care. *BJGP Open* 2018. [Internet]. <https://bjgpopen.org/content/1/4/bjgpopen17X101265>
8. Shinohara K, Efthimiou O, Ostinelli E, et al. Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and network meta-analysis. *BMJ Open* 2019;9:e027574
9. Health Canada. Drug Product Database. [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>

Page 2: Evidence

1. US Food and Drug Administration. Major Depressive Disorder: Developing Drugs for Treatment. Guidance for Industry. June 2018. [Internet]. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment>
2. Cipriani A, Furukawa T, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018;391:1357-1366
3. Munkholm K, Paluden-Muller A, Boesen K. Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. *BMJ Open* 2019;9:e024886
4. Furukawa T, Maruo K, Noma H, et al. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. *Acta Psychiatr Scand* 2018;137:450-458
5. Hieronymus F, Lisinski A, Nilsson S, Eriksson E. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post hoc analysis. *Lancet Psychiatry* 2019;6:745-752
6. Zimmerman M, Clark H, Multach M, et al. Have treatment studies become even less generalizable? A review of the inclusion and exclusion criteria used in placebo-controlled antidepressant efficacy trials published during the past 20 years. *Mayo Clin Proc* 2015;90:1180-86
7. Zimmerman M, Clark H, Multach M, et al. Symptom severity and generalizability of antidepressant efficacy trials. Changes during the past 20 years. *J Clin Psychopharmacol* 2016;36:153-56
8. Kirsch I, Deacon B, Huedo-Medin T, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med* 2008;5:e45
9. Jakobsen J, Katakam K, Schou A, et al. Selective serotonin reuptake inhibitors versus placebo in major depressive disorder. A systematic review with meta-analysis and trial sequential analysis. *BMC Psychiatry* 2017;17:58
10. Cipriani A, Salanti G, Furukawa T, et al. Antidepressants might work for people with major depression: where do we go from here? *Lancet Psychiatry* 2018;5:461-463
11. De Vries Y, Roest A, Beijers L, et al. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis. *Eur Neuropsychopharmacol* 2016;26:1752-1759
12. Gartlehner G, Hansen R, Morgan L, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder. An updated meta-analysis. *Ann Intern Med* 2011;155:772-785

13. Agency for Healthcare Research and Quality. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. December 2011. [Internet]. <https://effectivehealthcare.ahrq.gov/products/antidepressants-update/research>
14. Cipriani A, Santilli C, Furukawa T, et al. Escitalopram versus other antidepressive agents for depression. *Cochrane Database Syst Rev* 2009, Issue 2, CD006532
15. Cipriani A, La Ferla T, Fukawa T, et al. Sertraline versus other antidepressive agents for depression. *Cochrane Database Syst Rev* 2010, Issue 4, CD006117
16. Watanabe N, Omori I, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression (review). *Cochrane Database Syst Rev* 2011, Issue 12, CD006528
17. Cipriani A, Purgato M, Furukawa T, et al. Citalopram versus other anti-depressive agents for depression (review). *Cochrane Database Syst Rev* 2012, Issue 7, CD006534
18. Cipriani A, Koesters M, Furukawa T, et al. Duloxetine versus other anti-depressive agents for depression (review). *Cochrane Database Syst Rev* 2012, Issue 10, CD006533
19. Magni L, Purgato M, Gastaldon C, et al. Fluoxetine versus other types of pharmacotherapy for depression. *Cochrane Database Syst Rev* 2013, Issue 7, CD004185
20. Purgato M, Papola D, Gastaldon C, et al. Paroxetine versus other anti-depressive agents for depression (review). *Cochrane Database Syst Rev*, Issue 4, CD006531
21. Koesters M, Ostuzzi G, Guaiana G, et al. Vortioxetine for depression in adults. *Cochrane Database Syst Rev* 2017, Issue 2017, CD011520
22. Wagner G, Schultes M, Titscher V, et al. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis. *J Affective Dis* 2018;228:1-12
23. Tomlinson A, Efthimiou O, Boaden K, et al. Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis. *Evid Based Mental Health* 2019;22:61-66
24. Laughren T, Gobburu J, Temple R, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. *J Clin Psychiatry* 2011;72:1166-73
25. Zhang J, Mathis M, Sellers J, et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. *J Clin Psychiatry* 2015;76:8-14
26. Health Canada. Drug Product Database. Celexa (citalopram). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
27. US Food and Drug Administration. Drugs@FDA. Celexa (citalopram). <https://www.accessdata.fda.gov/scripts/cder/daf/>
28. Health Canada. Drug Product Database. Cipralox (escitalopram). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
29. US Food and Drug Administration. Drugs@FDA. Lexapro (escitalopram). <https://www.accessdata.fda.gov/scripts/cder/daf/>
30. Health Canada. Drug Product Database. Prozac (fluoxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
31. US Food and Drug Administration. Drugs@FDA. Prozac (fluoxetine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
32. Health Canada. Drug Product Database. Paxil (paroxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
33. Health Canada. Drug Product Database. Paxil CR (paroxetine controlled release). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
34. US Food and Drug Administration. Drugs@FDA. Paxil (paroxetine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
35. US Food and Drug Administration. Drugs@FDA. Paxil CR (paroxetine extended release). <https://www.accessdata.fda.gov/scripts/cder/daf/>
36. Health Canada. Drug Product Database. Zoloft (sertraline). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
37. US Food and Drug Administration. Drugs@FDA. Zoloft (sertraline). <https://www.accessdata.fda.gov/scripts/cder/daf/>
38. Health Canada. Drug Product Database. Viibryd (vilazodone). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
39. US Food and Drug Administration. Drugs@FDA. Viibryd (vilazodone). <https://www.accessdata.fda.gov/scripts/cder/daf/>
40. Health Canada. Drug Product Database. Trintellix (vortioxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
41. US Food and Drug Administration. Drugs@FDA. Trintellix (vortioxetine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
42. Health Canada. Drug Product Database. Effexor XR (venlafaxine extended release). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
43. US Food and Drug Administration. Drugs@FDA. Effexor XR (venlafaxine extended release). <https://www.accessdata.fda.gov/scripts/cder/daf/>
44. Health Canada. Drug Product Database. Pristiq (desvenlafaxine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
45. US Food and Drug Administration. Drugs@FDA. Pristiq (desvenlafaxine). <https://www.accessdata.fda.gov/scripts/cder/daf/>

46. Health Canada. Drug Product Database. Cymbalta (duloxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
47. US Food and Drug Administration. Drugs@FDA. Cymbalta (duloxetine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
48. Health Canada. Drug Product Database. Fetzima (levomilnacipran). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
49. US Food and Drug Administration. Drugs@FDA. Fetzima (levomilnacipran). <https://www.accessdata.fda.gov/scripts/cder/daf/>
50. Health Canada. Drug Product Database. Remeron (mirtazapine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
51. Health Canada. Drug Product Database. Remeron RD (mirtazapine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
52. US Food and Drug Administration. Drugs@FDA. Remeron (mirtazapine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
53. Health Canada. Drug Product Database. Wellbutrin SR (bupropion sustained release). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
54. Health Canada. Drug Product Database. Wellbutrin XL (bupropion extended release). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
55. US Food and Drug Administration. Drugs@FDA. Wellbutrin SR (bupropion sustained release). <https://www.accessdata.fda.gov/scripts/cder/daf/>
56. US Food and Drug Administration. Drugs@FDA. Wellbutrin XL (bupropion extended release). <https://www.accessdata.fda.gov/scripts/cder/daf/>
57. US Food and Drug Administration. Drugs@FDA. Wellbutrin (bupropion). <https://www.accessdata.fda.gov/scripts/cder/daf/>
58. Posternak M, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. *J Clin Psychiatry* 2005;66:148-158
59. Taylor M, Freemantle N, Geddes J, Bhagwagar Z. Early onset of selective serotonin inhibitor antidepressant action. *Arch Gen Psychiatry* 2006;63:1217-1223
60. Henssler J, Kurschus M, Franklin J, et al. Trajectories of acute antidepressant efficacy: how long to wait for response? *J Clin Psychiatry* 2018;79:17r11470
61. Furukawa T, Cipriani A, Cowen P, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. *Lancet Psychiatry* 2019;6:601-609
62. Furukawa T, Salanti G, Cowen P, et al. No benefit from flexible titration above minimal licenced dose in prescribing antidepressants for major depression: systematic review. *Acta Psychiatr Scand* 2019 Dec 31 [Epub ahead of print]
63. Davies P, Ijaz S, Williams C, et al. Pharmacological interventions for treatment-resistant depression in adults (Review). *Cochrane Database Syst Rev* 2019, Issue 12, CD010557
64. MacQueen G, Santaguida P, Keshavarz H, et al. Systematic review of clinical practice guidelines for failed antidepressant response in major depressive disorder, dysthymia, and subthreshold depression in adults. *Can J Psychiatry* 2017;62:11-23
65. Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: a meta analysis of 38 studies including 4511 patients. *Can J Psychiatry* 2016;61:29-43
66. Lopes Rocha F, Fuzikawa C, Riera R, et al. Antidepressant combination for major depression in incomplete responders – a systematic review. *J Affective Dis* 2013;144:1-6
67. Kessler D, MacNeill S, Tallon D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). *BMJ* 2018;363:k4218
68. Kato T, Furukawa T, Mantani A, et al. Optimising first- and second-line treatment strategies for untreated major depressive disorder – the SUND study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. *BMC Medicine* 2018;16:103

Pages 3-5: Drug Information Table

1. Health Canada. Drug Product Database. [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
2. McKesson Canada [Internet]. <https://www.mckesson.ca/>
3. BC PharmaCare Formulary Search [Internet]. <https://pharmacareformularysearch.gov.bc.ca/faces/Search.xhtml>
4. Health Canada. Drug Product Database. Celexa (citalopram). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
5. US Food and Drug Administration. Drugs@FDA. Celexa (citalopram). <https://www.accessdata.fda.gov/scripts/cder/daf/>
6. Health Canada. Drug Product Database. Cipralex (escitalopram). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
7. US Food and Drug Administration. Drugs@FDA. Lexapro (escitalopram). <https://www.accessdata.fda.gov/scripts/cder/daf/>
8. Health Canada. Drug Product Database. Prozac (fluoxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
9. US Food and Drug Administration. Drugs@FDA. Prozac (fluoxetine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
10. Health Canada. Drug Product Database. Paxil (paroxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>

11. Health Canada. Drug Product Database. Paxil CR (paroxetine controlled release). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
12. US Food and Drug Administration. Drugs@FDA. Paxil (paroxetine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
13. US Food and Drug Administration. Drugs@FDA. Paxil CR (paroxetine extended release). <https://www.accessdata.fda.gov/scripts/cder/daf/>
14. Health Canada. Drug Product Database. Zoloft (sertraline). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
15. US Food and Drug Administration. Drugs@FDA. Zoloft (sertraline). <https://www.accessdata.fda.gov/scripts/cder/daf/>
16. Health Canada. Drug Product Database. Viibryd (vilazodone). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
17. US Food and Drug Administration. Drugs@FDA. Viibryd (vilazodone). <https://www.accessdata.fda.gov/scripts/cder/daf/>
18. Health Canada. Drug Product Database. Trintellix (vortioxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
19. US Food and Drug Administration. Drugs@FDA. Trintellix (vortioxetine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
20. Health Canada. Drug Product Database. Effexor XR (venlafaxine extended release). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
21. US Food and Drug Administration. Drugs@FDA. Effexor XR (venlafaxine extended release). <https://www.accessdata.fda.gov/scripts/cder/daf/>
22. Health Canada. Drug Product Database. Pristiq (desvenlafaxine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
23. US Food and Drug Administration. Drugs@FDA. Pristiq (desvenlafaxine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
24. Health Canada. Drug Product Database. Cymbalta (duloxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
25. US Food and Drug Administration. Drugs@FDA. Cymbalta (duloxetine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
26. Health Canada. Drug Product Database. Fetzima (levomilnacipran). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
27. US Food and Drug Administration. Drugs@FDA. Fetzima (levomilnacipran). <https://www.accessdata.fda.gov/scripts/cder/daf/>
28. Health Canada. Drug Product Database. Remeron (mirtazapine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
29. Health Canada. Drug Product Database. Remeron RD (mirtazapine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
30. US Food and Drug Administration. Drugs@FDA. Remeron (mirtazapine). <https://www.accessdata.fda.gov/scripts/cder/daf/>
31. Health Canada. Drug Product Database. Wellbutrin SR (bupropion sustained release). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
32. Health Canada. Drug Product Database. Wellbutrin XL (bupropion extended release). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
33. US Food and Drug Administration. Drugs@FDA. Wellbutrin SR (bupropion sustained release). <https://www.accessdata.fda.gov/scripts/cder/daf/>
34. US Food and Drug Administration. Drugs@FDA. Wellbutrin XL (bupropion extended release). <https://www.accessdata.fda.gov/scripts/cder/daf/>
35. Laughren T, Gobburu J, Temple R, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. *J Clin Psychiatry* 2011;72:1166-73
36. Zhang J, Mathis M, Sellers J, et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. *J Clin Psychiatry* 2015;76:8-14
37. US Food and Drug Administration. Major Depressive Disorder: Developing Drugs for Treatment. Guidance for Industry. June 2018. [Internet]. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment>
38. Furukawa T, Cipriani A, Cowen P, et al. Optimal dose of selective serotonin inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. *Lancet Psychiatry* 2019; 6:601-609
39. Pae C, Wang SM, Han C, et al. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. *J Psychiatry Neurosci* 2015;40:174-186
40. De Vries YA, Roest A, Beijers L, et al. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: a meta-analysis. *Eur Neuropsychopharm* 2016;26:1752-59
41. Cipriani A, Furukawa T, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018;391:1357-1366
42. Tomlinson A, Efthimiou O, Boaden K, et al. Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis. *Evid Based Mental Health* 2019;22:61-66
43. Gartlehner G, Hansen R, Morgan L, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder. An updated meta-analysis. *Ann Intern Med* 2011;155:772-785

44. Agency for Healthcare Research and Quality. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. December 2011. [Internet]. <https://effectivehealthcare.ahrq.gov/products/antidepressants-update/research>
45. Wagner G, Schultes M, Titscher V, et al. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis. *J Affective Dis* 2018;228:1-12
46. Cipriani A, Santilli C, Furukawa T, et al. Escitalopram versus other antidepressive agents for depression. *Cochrane Database Syst Rev* 2009, Issue 2, CD006532
47. Cipriani A, La Ferla T, Fukawa T, et al. Sertraline versus other antidepressive agents for depression. *Cochrane Database Syst Rev* 2010, Issue 4, CD006117
48. Watanabe N, Omori I, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression (review). *Cochrane Database Syst Rev* 2011, Issue 12, CD006528
49. Cipriani A, Purgato M, Furukawa T, et al. Citalopram versus other anti-depressive agents for depression (review). *Cochrane Database Syst Rev* 2012, Issue 7, CD006534
50. Cipriani A, Koesters M, Furukawa T, et al. Duloxetine versus other anti-depressive agents for depression (review). *Cochrane Database Syst Rev* 2012, Issue 10, CD006533
51. Magni L, Purgato M, Gastaldon C, et al. Fluoxetine versus other types of pharmacotherapy for depression. *Cochrane Database Syst Rev* 2013, Issue 7, CD004185
52. Purgato M, Papola D, Gastaldon C, et al. Paroxetine versus other anti-depressive agents for depression (review). *Cochrane Database Syst Rev*, Issue 4, CD006531
53. Koesters M, Ostuzzi G, Guaiana G, et al. Vortioxetine for depression in adults. *Cochrane Database Syst Rev* 2017, Issue 2017, CD011520
54. Shinohara K, Efthimiou O, Ostinelli E, et al. Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and network meta-analysis. *BMJ Open* 2019;9:e027574
55. British Columbia Drug and Poison Information Centre (BC DPIC). Poison Management Manual. [Internet]. <http://www.dpic.org/content/new-poison-management-manual>
56. National Institute for Health and Care Excellence. Depression in adults: recognition and management. Clinical guidelines (CG90). [Internet]. <https://www.nice.org.uk/guidance/cg90>
57. Stewart E, Grewal K, Hudson H, et al. Clinical characteristics and outcomes associated with bupropion overdose: a Canadian perspective. *Clin Toxicol* 2019 Dec 12 [Epub ahead of print]
58. BC Centre for Disease Control. Venlafaxine: troubling toxicity in overdose. *BCMJ* 2007;49:10
59. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. *Br J Psychiatry* 2010;196:354-58
60. Baumgartner K, Doering M, Schwarz E. Vilazodone poisoning: a systematic review. *Clin Toxicol* 2019 Nov 28 [Epub ahead of print]
61. Fava G, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin inhibitor discontinuation: a systematic review. *Psychother Psychosom* 2015;84:72-81
62. Fava G, Benasi G, Lucente M, et al. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: a systematic review. *Psychother Psychosom* 2018;87:195-203
63. Henssler J, Heinz A, Brandt L, et al. Antidepressant withdrawal and rebound phenomena. *Dtsch Arztebl Int* 2019;116:355-61
64. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? *Addict Behav* 2019;97:111-21
65. Institute for Safe Medication Practices. QuarterWatch (2016 Annual Report) Part 1: Consumers at risk from drug withdrawal symptoms. July 13, 2017. [Internet]. <https://www.ismp.org/resources/quarterwatchtm-2016-annual-report-part-i-consumers-risk-drug-withdrawal-symptoms>
66. Alberti S, Chiesa A, Andrisano C, et al. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. *J Clin Psychopharmacol* 2015;35:296-303
67. Khin N, Kronstein P, Yang P, et al. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials. *J Clin Psychiatry* 2015;76:1060-63
68. Kronstein P, Ishida E, Khin N, et al. Summary of findings from the FDA regulatory science forum on measuring sexual dysfunction in depression trials. *J Clin Psychiatry* 2015;76:1050-59
69. Reichenpfeiffer U, Gartlehner G, Morgan L, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. *Drug Saf* 2014;37:19-31
70. Jacobsen P, Mahabeshwarkar A, Chen Y, et al. Effect of vortioxetine vs escitalopram on sexual dysfunction in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. *J Sex Med* 2015;12:2036-48
71. Bala A, Nguyen H, Hellstrom W. Post-SSRI sexual dysfunction. *Sex Med Rev* 2018;6:29-34
72. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommendations on signals. SNRI SSRI persistent sexual dysfunction after drug withdrawal. 2019. [Internet]. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-may-2019-prac-meeting_en.pdf

73. Therapeutics Initiative. Therapeutics Letter 113. How well do you know your anticholinergic (antimuscarinic) drugs? 2018. [Internet]. <https://www.ti.ubc.ca/2018/09/10/113-anticholinergic-antimuscarinic-drugs/>
74. Gafoor R, Booth H, Gulliford M. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. *BMJ* 2018;361:k1951
75. Serreti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. *J Clin Psychiatry* 2010;71:1259-72
76. US Food and Drug Administration. Drugs@FDA. Viibryd (vilazodone). NDA 022567. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000MedR.pdf
77. US Food and Drug Administration. Cymbalta (duloxetine hydrochloride). Drug Approval Package. Major Depressive Disorder. NDA 021427 [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021427_s000_Cymbalta_BioPharmr_P1.pdf
78. Health Canada. Summary Safety Review. Antidepressants – Assessing the potential risk of serious eye disorder (angle closure-glaucoma). 2016. [Internet]. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/>
79. US Food and Drug Administration. Drugs@FDA. Wellbutrin (bupropion). NDA 018644. 1985. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018644Orig1s000rev.pdf
80. Stall N, Godwin J, Juurlink D. Bupropion abuse and overdose. *CMAJ* 2014;186:1015

Page 6: Drug Interaction Table

1. Indiana University. Drug Interactions Flockhart Table. [Internet]. <https://drug-interactions.medicine.iu.edu/MainTable.aspx>
2. Health Canada. Drug Product Database. Celexa (citalopram). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
3. Lexicomp. Product Monograph. Citalopram: Drug Information. [Internet]. <https://www.uptodate.com/contents/citalopram-drug-information>
4. Health Canada. Drug Product Database. CipraleX (escitalopram). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
5. Lexicomp. Product Monograph. Escitalopram: Drug Information. [Internet]. <https://www.uptodate.com/contents/escitalopram-drug-information>
6. Health Canada. Drug Product Database. Prozac (fluoxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
7. Lexicomp. Product Monograph. Fluoxetine: Drug Information. [Internet]. <https://www.uptodate.com/contents/fluoxetine-drug-information>
8. Health Canada. Drug Product Database. Luvox (fluvoxamine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
9. Lexicomp. Product Monograph. Fluvoxamine: Drug Information. [Internet]. <https://www.uptodate.com/contents/fluvoxamine-drug-information>
10. Health Canada. Drug Product Database. Paxil (paroxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
11. Lexicomp. Product Monograph. Paroxetine: Drug Information. [Internet]. <https://www.uptodate.com/contents/paroxetine-drug-information>
12. Health Canada. Drug Product Database. Zoloft (sertraline). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
13. Lexicomp. Product Monograph. Sertraline: Drug Information. [Internet]. <https://www.uptodate.com/contents/sertraline-drug-information>
14. Health Canada. Drug Product Database. Viibryd (vilazodone). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
15. Lexicomp. Product Monograph. Vilazodone: Drug Information. [Internet]. <https://www.uptodate.com/contents/vilazodone-drug-information>
16. Health Canada. Drug Product Database. Trintellix (vortioxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
17. Lexicomp. Product Monograph. Vortioxetine: Drug Information. [Internet]. <https://www.uptodate.com/contents/vortioxetine-drug-information>
18. Health Canada. Drug Product Database. Pristiq (desvenlafaxine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
19. Lexicomp. Product Monograph. Desvenlafaxine: Drug Information. [Internet]. <https://www.uptodate.com/contents/desvenlafaxine-drug-information>
20. Health Canada. Drug Product Database. Cymbalta (duloxetine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>

21. Lexicomp. Product Monograph. Duloxetine: Drug Information. [Internet]. <https://www.uptodate.com/contents/duloxetine-drug-information>
22. Health Canada. Drug Product Database. Fetzima (levomilnacipran). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
23. Lexicomp. Product Monograph. Levomilnacipran: Drug Information. [Internet]. <https://www.uptodate.com/contents/levomilnacipran-drug-information>
24. Health Canada. Drug Product Database. Effexor XR (venlafaxine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
25. Lexicomp. Product Monograph. Venlafaxine: Drug Information. [Internet]. <https://www.uptodate.com/contents/venlafaxine-drug-information>
26. Health Canada. Drug Product Database. Remeron (mirtazapine). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
27. Lexicomp. Product Monograph. Mirtazapine: Drug Information. [Internet]. <https://www.uptodate.com/contents/mirtazapine-drug-information>
28. Health Canada. Drug Product Database. Wellbutrin XL (bupropion). [Internet]. <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
29. Lexicomp. Product Monograph. Bupropion: Drug Information. [Internet]. <https://www.uptodate.com/contents/bupropion-drug-information>
30. FDA. Drugs @ FDA Database. Forfivo XL (bupropion). [Internet] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022497s004lbl.pdf
31. Health Canada. Drug Product Database. Contrave (naltrexone/bupropion). [Internet]. https://pdf.hres.ca/dpd_pm/00043849.PDF
32. BC Cancer Agency Tamoxifen Summary for Professionals. [Internet]. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Tamoxifen_monograph.pdf
33. Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. *BMJ* 2016;354:i5309
34. Geoffrey A, Pollack S, Bruno P, Thiele E. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. *Epilepsia* 2015;56:1246-1251
35. Anglin R, Yuan Y, Moayyedi P, Tse F, et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. *Am J Gastroenterol* 2014;109:811-9
36. Schelleman H, Brensinger CM, Bilker WB, Hennessy S. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. *PLoS ONE* 2011;6:e21447
37. Na K, Jung H, Cho S, Cho S. Can we recommend mirtazapine and bupropion for patients at risk for bleeding? A systematic review and meta-analysis. *J Affective Dis* 2018;225:221-226
38. Foong A, Gindrod K, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). *Can Fam Phys* 2018;64:720-727
39. Credible Meds. FAQs for Healthcare Professionals. [Internet]. <https://crediblemeds.org/healthcare-providers/professionalfaq/>

Page 7: Antidepressant Withdrawal and Tapering

1. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? *Addict Behav* 2019;97:111-121
2. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. *Lancet Psychiatry* 2019;6:538-546
3. National Institute for Care and Health Excellence. Depression in adults: recognition and management. Clinical guidelines [CG90]. 2018. [Internet]. <https://www.nice.org.uk/guidance/cg90/>
4. Lerner A, Klein M. Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. *Brain Communications* 2019;1:1-23
5. Chouinard G, Chouinard V. New classification of selective serotonin reuptake inhibitor withdrawal. *Psychother Psychosom* 2015;84:63-71
6. Hensler J et al. Antidepressant withdrawal and rebound phenomena. *Dtsch Arztebl Int* 2019; 116:355-61
7. Ruhe H, Horikx A, Van Avendonk, et al. Correspondence. *Lancet Psychiatry* 2019;6:561-62
8. Ruhe H, Horikx A, Van Avendonk, et al. Supplement. *Lancet Psychiatry* 2019;6:561-62. [Internet]. [https://www.thelancet.com/cms/10.1016/S2215-0366\(19\)30182-8/attachment/91d6d8f3-74b5-4ba2-a11c-bb366f28e5da/mmc1.pdf](https://www.thelancet.com/cms/10.1016/S2215-0366(19)30182-8/attachment/91d6d8f3-74b5-4ba2-a11c-bb366f28e5da/mmc1.pdf)

Page 8: Discussion

1. US Food and Drug Administration. Major Depressive Disorder: Developing Drugs for Treatment. Guidance for Industry. June 2018. [Internet]. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment>
2. Cipriani A, Furukawa T, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018;391:1357-1366
3. Furukawa T, Cipriani A, Cowen P, et al. Optimal dose of selective serotonin inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. *Lancet Psychiatry* 2019; 6:601-609
4. Eveleigh R, Speckens A, Van Weel C, et al. Patients' attitudes to discontinuing non-indicated long-term antidepressant use: barriers and facilitators. *Ther Adv Psychopharmacol* 2019;9:1-9
5. The Lancet Psychiatry. Measuring success: the problem with primary outcomes. *Lancet Psychiatry* 2020;7:1
6. Turner E, Rosenthal R. Efficacy of antidepressants. Is not an absolute measure, and it depends on how clinical significance is defined. *BMJ* 2008;336:516-7